BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...
In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine ...
The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease. A new analysis of the real-world outcomes of young ...
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq. Enfortumab vedotin plus pembrolizumab in metastatic ...
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced ...
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC). This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This ...
ProPeer Resources, a leading independent review organization specializing in utilization management and peer review services, today announced it has earned a three-year Utilization Management (UM) ...
Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results